Across TCGA pan-cancer cohorts, PADI1 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PADI1 data layer compared with 26 for mass-spec protein and 6 for mutation status.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PADI1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PADI1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.
HNSC and LUAD are the cancer types where PADI1 mass-spec protein most reproducibly stratifies survival.